Skip to main content

25-05-2020 | Neurodegeneration | Video

EAN 2020 | Resource gaps identified ahead of intrathecal Huntington’s disease treatments

Jean-Marc Burgunder outlines the need for adequate planning by capacity-constrained healthcare systems to ensure the delivery of upcoming intrathecally administered disease-modifying therapies in patients with Huntington’s disease (6:04).

Funding for independent interviews at EAN 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.